Myriad Genetics Included in Forbes America’s Best Employers 2025 List

GlobeNewswire
02-19

SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of America’s Best Employers 2025. This prestigious recognition is presented in collaboration with Statista, the world-leading statistics portal and industry ranking provider.

“Working at Myriad Genetics means being part of a dynamic team dedicated to empowering every individual by revealing the answers inside each of us. Our teammates are driven to innovate solutions that change lives,” said Shereen Solaiman, chief people officer, Myriad Genetics. “I want to commend our teammates, who are dedicated to advancing health and wellbeing for all.”

Being included on the Forbes list is the latest accolade for the company. Last year, 84% of Myriad employees said it’s a Great Place To Work — 27 percentage points higher than the average U.S. company.

Forbes and Statista selected America’s Best Employers 2025 through an independent survey from a vast sample of more than 217,000 U.S. employees working for companies employing at least 1,000 people within the U.S. More than 6.5 million employer evaluations were considered. The final score is based on two types of evaluations: personal (those given by employees themselves) and public (those given by friends and family members of employees, or members of the public who work in the same industry), with a much higher weighting for personal evaluations.

For more information about careers at Myriad, please visit: https://myriad.com/careers/.

About Statista
Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, business-relevant data, and various market and consumer studies and surveys.

About Myriad Genetics
Myriad Genetics is a leading genetic and genomic tumor testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com


免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10